Roche Holding AG : There is still some upside potential

03/18/2022 | 02:50am EDT

long trade Target price hit

Entry price : 362.5CHF | Target : 400CHF | Stop-loss : 330CHF | Potential : 10.34%

Roche Holding AG's shares display attractive technical aspects to anticipate a comeback of the underlying trend. Investors have an opportunity to buy the stock and target the CHF 400.

Summary

• The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

• Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
• Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
• The company is in a robust financial situation considering its net cash and margin position.
• Analyst opinion has improved significantly over the past four months.

Weaknesses

• According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
• The company's enterprise value to sales, at 4.69 times its current sales, is high.
• The company appears highly valued given the size of its balance sheet.
• For the last few months, analysts have been revising downwards their earnings forecast.
• Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

© MarketScreener.com 2022

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.